Nephrogenic Fibrosing Dermopathy
"Nephrogenic Fibrosing Dermopathy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic, acquired, idiopathic, progressive eruption of the skin that occurs in the context of RENAL FAILURE. It is sometimes accompanied by systemic fibrosis. The pathogenesis seems to be multifactorial, with postulated involvement of circulating fibrocytes. There is a strong association between this disorder and the use of gadolinium-based contrast agents.
| Descriptor ID |
D054989
|
| MeSH Number(s) |
C17.800.553 C23.550.355.550
|
| Concept/Terms |
Nephrogenic Fibrosing Dermopathy- Nephrogenic Fibrosing Dermopathy
- Dermopathies, Nephrogenic Fibrosing
- Dermopathy, Nephrogenic Fibrosing
- Fibrosing Dermopathies, Nephrogenic
- Fibrosing Dermopathy, Nephrogenic
- Nephrogenic Fibrosing Dermopathies
- Nephrogenic Systemic Fibrosis
- Fibroses, Nephrogenic Systemic
- Fibrosis, Nephrogenic Systemic
- Nephrogenic Systemic Fibroses
- Systemic Fibroses, Nephrogenic
- Systemic Fibrosis, Nephrogenic
|
Below are MeSH descriptors whose meaning is more general than "Nephrogenic Fibrosing Dermopathy".
Below are MeSH descriptors whose meaning is more specific than "Nephrogenic Fibrosing Dermopathy".
This graph shows the total number of publications written about "Nephrogenic Fibrosing Dermopathy" by people in this website by year, and whether "Nephrogenic Fibrosing Dermopathy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 5 | 0 | 5 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 0 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nephrogenic Fibrosing Dermopathy" by people in Profiles.
-
Lyapustina T, Goldfine C, Rhyee S, Babu KM, Griswold MK. Evaluating the Patient with Reported Gadolinium-Associated Illness. J Med Toxicol. 2019 Jan; 15(1):36-44.
-
Martin DR, Kalb B, Mittal A, Salman K, Vedantham S, Mittal PK. Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease. Radiology. 2018 01; 286(1):113-119.
-
Goyal A, Linskey KR, Kay J, Duncan LM, Nazarian RM. Differential Expression of Hedgehog and Snail in Cutaneous Fibrosing Disorders: Implications for Targeted Inhibition. Am J Clin Pathol. 2016 Dec; 146(6):709-717.
-
Todd DJ, Kay J. Gadolinium-Induced Fibrosis. Annu Rev Med. 2016; 67:273-91.
-
Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, Latz E, Gravallese EM, Marshak-Rothstein A, Kay J. Gadolinium-based compounds induce NLRP3-dependent IL-1? production and peritoneal inflammation. Ann Rheum Dis. 2015 Nov; 74(11):2062-9.
-
Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology (Oxford). 2014 Sep; 53(9):1613-7.
-
Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014 Jul; 69(7):661-8.
-
Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol. 2013 May; 35(3):351-6.
-
Lima XT, Alora-Palli MB, Kimball AB, Kay J. Validation of a screening instrument for nephrogenic systemic fibrosis. Arthritis Care Res (Hoboken). 2013 Apr; 65(4):637-42.
-
Bernstein EJ, Schmidt-Lauber C, Kay J. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol. 2012 Aug; 26(4):489-503.